Sulfadoxine-pyrimethamine (SP) is currently recommended by the World Health Organization for
use as intermittent preventive treatment against malaria in pregnancy (IPTp) in areas of
moderate to high malaria transmission. However, in some locales malaria parasites have lost
sensitivity to SP, compromising its protective effect. Dihydroartemisinin-piperaquine (DP) is
a candidate replacement for SP. This trial is designed to confirm the cardio-safety of DP
compared to SP amongst pregnant women in Tanzania.